Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma. Issue 5 (29th April 2021)

• Record Type: Journal Article
• Authors: Stenman, Adam; Backman, Samuel; Johansson, Klara; Paulsson, Johan O; Stålberg, Peter; Zedenius, Jan; Juhlin, C Christofer
• Is Part Of: Endocrine-related cancer. Volume 28:Issue 5(2021)
• Page Start: 337
• Page End: 351
• Publication Date: 2021-04-29
• Subjects: whole-genome sequencing -- RNA sequencing -- mutation -- pediatric thyroid cancer -- papillary thyroid carcinoma; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-20-0464
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : Pediatric papillary thyroid carcinomas (pPTCs) are often indolent tumors with excellent long-term outcome, although subsets of cases are clinically troublesome and recur. Although it is generally thought to exhibit similar molecular aberrancies as their counterpart tumors in adults, the pan-genomic landscape of clinically aggressive pPTCs has not been previously described. In this study, five pairs of primary and synchronously metastatic pPTC from patients with high-risk phenotypes were characterized using parallel whole-genome and -transcriptome sequencing. Primary tumors and their metastatic components displayed an exceedingly low number of coding somatic mutations and gross chromosomal alterations overall, with surprisingly few shared mutational events. Two cases exhibited one established gene fusion event each ( SQSTM1 - NTRK3 and NCOA4 - RET ) in both primary and metastatic tissues, and one case each was positive for a BRAF V600E mutation and a germline truncating CHEK2 mutation, respectively. One single case was without apparent driver events and was considered as a genetic orphan. Non-coding mutations in cancer-associated regions were generally not present. By expressional analyses, fusion-driven primary and metastatic pPTC clustered separately from the mutation-driven cases and the sole genetic orphan. We conclude that pPTCs are genetically indolent tumors with exceedingly stable genomes. Several mutations found exclusively in the metastatic samples which may represent novel genetic events that drive the metastatic behavior, and the differences in mutational compositions suggest early clonal divergence between primary tumors and metastases. Moreover, an overrepresentation of mutational and expressional dysregulation of immune regulatory pathways was noted among fusion-positive pPTC metastases, suggesting that these tumors might facilitate spread through immune evasive mechanisms.